Centessa Pharmaceuticals Announces Promising Interim Phase 1 Data for ORX750: A Potential Breakthrough in Treating Sleep Disorders’
BOSTON and LONDON September 10, 2024’ Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, has unveiled encouraging interim data from their ongoing Phase 1 clinical trial for ORX750, a novel and highly potent orexin receptor 2 (OX2R) agonist. The study, conducted with acutely sleep-deprived healthy volunteers, showed that ORX750 could significantly improve wakefulness, paving the way for future treatments for sleep disorders like narcolepsy and idiopathic hypersomnia.
Set against the backdrop of an increasing need for effective sleep disorder interventions, the results demonstrated that ORX750 markedly enhances mean sleep latency, a measure of the time it takes for a person to fall asleep. The Maintenance of Wakefulness Test (MWT) results indicated that both 1.0 mg and 2.5 mg doses of ORX750 led to clinically meaningful and statistically significant improvements in mean sleep latency when compared to a placebo. Notably, the 2.5 mg dose achieved what the researchers described as
ormative wakefulness, posting a mean sleep latency of 32 minutes as measured by the MWT.
These findings are incredibly promising and serve as a critical milestone for Centessa Pharmaceuticals in our quest to develop transformational medicines for patients with sleep disorders, noted Centessa’s CEO in a recent statement. The data suggest that ORX750 could restore wakefulness in a manner that is both effective and safe.
Safety and tolerability are paramount when introducing any new pharmaceutical intervention. Reassuringly, ORX750 demonstrated an excellent safety profile, with no frequent on-target adverse events commonly associated with other OX2R agonists. Furthermore, there were no observed cases of hepatotoxicity or visual disturbances at any of the doses tested (1.0 mg, 2.0 mg, and 2.5 mg) as of the data cutoff date.
Given the robust interim findings, Centessa Pharmaceuticals plans to expedite the advancement of ORX750 into Phase 2 clinical trials. These trials, set to commence in the fourth quarter of 2024, will investigate the drug’s efficacy in patients with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).
The continuation and expansion of this research underscore the potential of ORX750 to serve as a pivotal therapeutic option for those suffering from severe sleep disorders. As Centessa Pharmaceuticals moves forward, the medical community and patients alike will keenly watch the developments, hopeful for a new, effective treatment on the horizon.
Comments